Download Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Ovarian Cancer Treatment Market: By Type of Cancer, By Drug Class, By Distribution Channel and Region Forecast 2020-2031
Ovarian Cancer Treatment Market: By Type of Cancer, By Drug Class, By Distribution Channel and Region Forecast 2020-2031
Ovarian Cancer Treatment Market size was valued at US$ 2.36 billion in 2024 and is expected to reach US$ 3.81 billion by 2031, growing at a significant CAGR of 7.1% from 2025-2031. Ovarian cancer is a type of cancer, which affects ovaries it causes rapid and abnormal increase of cell growth in ovaries. The exact cause of cancer is still unknown. An epithelial tumour, germ cell tumour and primary peritoneal carcinoma are types of ovarian cancer. Common symptoms include pressure in pelvis or lower back, changes in bowel movements, tiredness or low energy and more frequent urination. In most of the ovarian cancer cases, cancer will not be diagnosed until it has progressed to an advanced stage. Ovarian cancer is one of most common cause of cancer deaths in women. Thereby need for development of the more effective drugs in treatment of ovarian cancer. Companies operating in ovarian cancer market investing in developing new drug therapies and finding newer molecular targets to treat ovarian cancer.
For instance, Vintafolide an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. and faltetuzumab a monoclonal antibody being investigated for the treatment of ovarian cancer this was developed by Morphotek, Inc. The introduction of new drug therapies like gene therapy, radiation therapy and targeted drug therapy are projected to improve ovarian cancer market revenue growth over forecast period. Global ovarian cancer market currently dominated by generic drugs and development of more effective drugs is challenging for market players. Some of the new drugs like avastin, lynparza and yondelis are approved in recent years to treat cancer and these drugs are slowly capturing market share.
Study Period
2025-2031Base Year
2024CAGR
7.1%Largest Market
EuropeFastest Growing Market
North-America
Increase in incidence of ovarian cancer worldwide is driving the ovarian cancer treatment market. According to WHO, an estimated 238,700 woman are diagnosed with ovarian cancer in 2012. The increase in older woman population, rising government funding and raising health care awareness able to grow market over the forecast period.
According to ovarian cancer research fund alliance, the rate of prevalence of ovarian cancer is higher in woman between 55 to 66 years, many of the cancer foundations are funding to educate patients and healthcare professionals regarding symptoms and treatment options for ovarian cancer which may impact ovarian cancer market revenue growth positively over a forecast period. However, availability of generic drugs, lack of accurate diagnosis of ovarian cancer, and patient expiry of the key patented drugs like gemzar, taxol and paraplatin are expected to hamper the market.
Geographically ovarian cancer treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the market due to rising number of ageing population. According to American cancer society, in U.S. about 22,440 women will receive a new diagnosis of ovarian cancer and about 14,080 women will die from ovarian cancer in 2017. Europe is largest market as the incidence rates of ovarian cancer is increased in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 2.36 billion |
|
Market Size in 2031 |
US$ 3.81 billion |
|
Market CAGR |
7.1% |
|
By Type of Cancer |
|
|
Drug Class |
|
|
Distribution Channel |
|
Download Free Sample Report
The ovarian cancer treatment market size was valued at US$ 2.36 billion in 2024 and is expected to reach US$ 3.81 billion by 2031, growing at a significant CAGR of 7.1% from 2025-2031
The market key players are: Johnson & Johnson Services Inc. (U.S.) Eli Lilly and Company (U.S.) Novogen Limited (Australia) Aeterna Zentaris Inc. (U.S) GlaxoSmithKline plc (UK) Boehringer Ingelheim GmbH (Germany) F. Hoffmann-La Roche AG (Switzerland)
The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
North-America is the fastest-growing region in the market.
| 1. Executive Summary |
| 2. Global Ovarian Cancer Treatment Market Introduction |
| 2.1. Global Ovarian Cancer Treatment Market – Taxonomy |
| 2.2. Global Ovarian Cancer Treatment Market –Definitions |
| 2.2.1. Drug Class |
| 2.2.2. Cancer Type |
| 2.2.3. Distribution Channel |
| 2.2.4. Region |
| 3. Global Ovarian Cancer Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Ovarian Cancer Treatment Market Dynamic Factors - Impact Analysis |
| 3.6. Ovarian Cancer Epidemiology |
| 3.7. Pipeline Analysis |
| 3.8. Target or Mechanism of Action Analysis |
| 3.9. Patient Journey |
| 3.10. Collaborations, Distribution Agreements, and Acquisitions |
| 4. Global Ovarian Cancer Treatment Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Ovarian Cancer Treatment Market, By Drug Class, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 5.1. Chemotherapeutic Agents |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Targeted Therapy Drugs |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Immune System Modulators |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Hormones |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Ovarian Cancer Treatment Market Forecast, By Cancer Type, 2020 - 2024 and Forecast, 2025 - 2031 |
| 6.1. Epithelial Ovarian Tumor |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Ovarian Germ Cell Tumor |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Ovarian Stomatal Tumor |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Primary Peritoneal Carcinoma |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7. Global Ovarian Cancer Treatment Market, By Distribution Channel, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Ovarian Cancer Treatment Market Forecast, By Region, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Ovarian Cancer Treatment Market - Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Region, 2024 - 2030 |
| 9. North America Ovarian Cancer Treatment Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 9.1. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Chemotherapeutic Agents |
| 9.1.2. Targeted Therapy Drugs |
| 9.1.3. Immune System Modulators |
| 9.1.4. Hormones |
| 9.2. Cancer Type Analysis, 2017 - 2021 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Epithelial Ovarian Tumor |
| 9.2.2. Ovarian Germ Cell Tumor |
| 9.2.3. Ovarian Stomatal Tumor |
| 9.2.4. Primary Peritoneal Carcinoma |
| 9.2.5. Others |
| 9.3. Distribution Channel Type Analysis, 2017 - 2021 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. Hospital Pharmacies |
| 9.3.2. Retail Pharmacies |
| 9.3.3. Others |
| 9.4. Country Analysis 2017 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. U.S. |
| 9.4.2. Canada |
| 9.5. North America Ovarian Cancer Treatment Market - Opportunity Analysis Index, By Drug Class, Cancer Type, and Country, 2024 - 2030 |
| 9.6. North America Ovarian Cancer Treatment Market Dynamics – Trends |
| 10. Europe Ovarian Cancer Treatment Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 10.1. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Chemotherapeutic Agents |
| 10.1.2. Targeted Therapy Drugs |
| 10.1.3. Immune System Modulators |
| 10.1.4. Hormones |
| 10.2. Cancer Type Analysis, 2017 - 2021 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Epithelial Ovarian Tumor |
| 10.2.2. Ovarian Germ Cell Tumor |
| 10.2.3. Ovarian Stomatal Tumor |
| 10.2.4. Primary Peritoneal Carcinoma |
| 10.2.5. Others |
| 10.3. Distribution Channel Type Analysis, 2017 - 2021 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Hospital Pharmacies |
| 10.3.2. Retail Pharmacies |
| 10.3.3. Others |
| 10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. Spain |
| 10.4.4. France |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Rest of Europe |
| 10.5. Europe Ovarian Cancer Treatment Market - Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel and Country, 2024 - 2030 |
| 10.6. Europe Ovarian Cancer Treatment Market Dynamics – Trends |
| 11. Asia-Pacific Ovarian Cancer Treatment Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 11.1. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Chemotherapeutic Agents |
| 11.1.2. Targeted Therapy Drugs |
| 11.1.3. Immune System Modulators |
| 11.1.4. Hormones |
| 11.2. Cancer Type Analysis, 2017 - 2021 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Epithelial Ovarian Tumor |
| 11.2.2. Ovarian Germ Cell Tumor |
| 11.2.3. Ovarian Stomatal Tumor |
| 11.2.4. Primary Peritoneal Carcinoma |
| 11.2.5. Others |
| 11.3. Distribution Channel Type Analysis, 2017 - 2021 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Hospital Pharmacies |
| 11.3.2. Retail Pharmacies |
| 11.3.3. Others |
| 11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Ovarian Cancer Treatment Market - Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Country, 2024 - 2030 |
| 11.6. Asia-Pacific Ovarian Cancer Treatment Market Dynamics – Trends |
| 12. Latin America Ovarian Cancer Treatment Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 12.1. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Chemotherapeutic Agents |
| 12.1.2. Targeted Therapy Drugs |
| 12.1.3. Immune System Modulators |
| 12.1.4. Hormones |
| 12.2. Cancer Type Analysis, 2017 - 2021 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Epithelial Ovarian Tumor |
| 12.2.2. Ovarian Germ Cell Tumor |
| 12.2.3. Ovarian Stomatal Tumor |
| 12.2.4. Primary Peritoneal Carcinoma |
| 12.2.5. Others |
| 12.3. Distribution Channel Type Analysis, 2017 - 2021 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Hospital Pharmacies |
| 12.3.2. Retail Pharmacies |
| 12.3.3. Others |
| 12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Rest of Latin America |
| 12.5. Latin America Ovarian Cancer Treatment Market - Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Country, 2024 - 2030 |
| 12.6. Latin America Ovarian Cancer Treatment Market Dynamics – Trends |
| 13. Middle East and Africa Ovarian Cancer Treatment Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) |
| 13.1. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Chemotherapeutic Agents |
| 13.1.2. Targeted Therapy Drugs |
| 13.1.3. Immune System Modulators |
| 13.1.4. Hormones |
| 13.2. Cancer Type Analysis, 2017 - 2021 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Epithelial Ovarian Tumor |
| 13.2.2. Ovarian Germ Cell Tumor |
| 13.2.3. Ovarian Stomatal Tumor |
| 13.2.4. Primary Peritoneal Carcinoma |
| 13.2.5. Others |
| 13.3. Distribution Channel Type Analysis, 2017 - 2021 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1. Hospital Pharmacies |
| 13.3.2. Retail Pharmacies |
| 13.3.3. Others |
| 13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Saudi Arabia |
| 13.4.2. South Africa |
| 13.4.3. Rest of MEA |
| 13.5. MEA Ovarian Cancer Treatment Market - Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Country, 2024 - 2030 |
| 13.6. MEA Ovarian Cancer Treatment Market Dynamics – Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Eli Lilly and Company |
| 14.2.2. Johnson & Johnson Services, Inc. |
| 14.2.3. Kazia Therapeutics |
| 14.2.4. Aeterna Zentaris Inc |
| 14.2.5. GlaxoSmithKline plc |
| 14.2.6. F. Hoffmann-La Roche AG |
| 14.2.7. AbbVie Inc., |
| 14.2.8. Pfizer Inc., |
| 14.2.9. AstraZeneca plc |
| 14.2.10. Immunogen |
| 14.2.11. Novartis |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.